NU-RISE is a Portugal-based startup focused on developing nuclear radiation sensors and equipment for various industries, research instrumentation, and medical applications. Founded in 2015, the company aims to help doctors better target cancer and protect patients from unnecessary radiation. NU-RISE recently initiated in-vitro trials of a new device for in-vivo and real-time dosimetry, addressing the lack of radiation monitoring in prostate and breast brachytherapy. The startup received a €100.00K investment in its Seed Round from Portugal Ventures on 13 January 2021.
NU-RISE's innovative approach to radiation monitoring and its potential impact on improving cancer treatment make it an intriguing investment opportunity. The startup's focus on manufacturing nuclear radiation sensors positions it at the intersection of technology and healthcare, tapping into a high-growth market with significant unmet needs.
The recent investment by Portugal Ventures signifies confidence in NU-RISE's technology and business potential. The startup's dedication to advancing medical applications of its products aligns with the larger trend of technology-driven innovations in healthcare, making it an attractive prospect for venture capitalists seeking impactful opportunities in the medical technology sector.
Taxonomy:
nuclear radiation, medical equipment, cancer treatment, radiation sensors, oncology, in-vitro trials, dosimetry, brachytherapy, real-time monitoring, cancer research, prostate treatment, breast cancer, innovation
Portugal
